SEARCH

SEARCH BY CITATION

References

  • 1
    Sloan JA, Dueck A, Erickson PA, et al. Analysis and interpretation of results based on patient-reported outcomes. Value Health 2007;10(Suppl. 2):S10615.
  • 2
    Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, Version 3.0. DCTD, NCI, NIH, DHHS, 2006. Available from: http://ctep.cancer.gov[Accessed March 31, 2003].
  • 3
    Moertel CG, Hanley JA. The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer 1976;38:38894.
  • 4
    Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005;23:866470.
  • 5
    Ballman KV, Buckner JC, Brown PD, et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol 2007;9:2938.
  • 6
    Sloan JA, Dueck A, Frost MH, et al. Applying QOL assessments: solutions for oncology clinical practice and research, part 1. Curr Probl Cancer 2005;29:267351.
  • 7
    Sloan JA, Dueck A, Frost MH, et al. Applying QOL assessments: solutions for oncology clinical practice and research, part 2. Curr Probl Cancer 2006;30:235331.
  • 8
    Dueck A, Halyard MY, Frost MH, Sloan JA. Meeting on the FDA draft guidance on patient-reported outcomes. Patient-Reported Outcomes Newsl 2006;36:14.